Molecular epidemiologic features of inflammatory breast cancer: A comparison between Egyptian and US patients

An Chi Lo, Celina G. Kleer, Mousumi Banerjee, Sherif Omar, Hussein Khaled, Saad Eissa, Ahmed Hablas, Julie A. Douglas, Sharon H. Alford, Sofia D. Merajver, Amr S. Soliman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Inflammatory breast cancer (IBC) is a lethal form of breast cancer with unknown etiology. A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors. Methods: We used tumor blocks and demographic, epidemiologic, and clinical data of 48 IBC patients from Egypt and 12 patients from the United States. We counted tumor emboli in tumors before and after immunohistochemical staining with lymphatic vessel endothelial receptor-1 (LYVE-1), and measured the expression of RhoC GTPase protein in the two groups. Results: Erythema, edema, and peau d'orange were found in 77% of the Egyptian patients as compared with 29% found in the US patients (P = 0.02). The number of tumor emboli was significantly higher in tumors from Egypt (mean ± SD, 14.1 ± 14.0) than in the tumors from the United States (5.0 ± 4.0, P = 0.01). The number of tumor emboli in LYVE-1 positive vessels was higher in tumors from Egypt (3.5 ± 2.8) than tumors from the United States (1.6 ± 0.5, P = 0.15). We detected a high level of RhoC in 87% of the tumors from Egypt and 14% of the tumors from the United States (P = 0.0003). Conclusion: Patients from Egypt have a more aggressive form of IBC than those in the United States. Our analysis of IBC patients shows that distinct molecular phenotypes can be found when these two study populations are compared. Future studies should explore the epidemiologic and environmental exposures and the genetic factors that might lead to the different clinical and molecular features of IBC in patients from these two countries.

Original languageEnglish (US)
Pages (from-to)141-147
Number of pages7
JournalBreast Cancer Research and Treatment
Volume112
Issue number1
DOIs
StatePublished - Nov 1 2008

Fingerprint

Inflammatory Breast Neoplasms
Egypt
Neoplasms
Embolism
Lymphatic Vessels
Epidemiologic Factors
Phenotype
GTP Phosphohydrolases
Environmental Exposure
Erythema
Edema

Keywords

  • Inflammatory breast cancer
  • International
  • LYVE-1
  • Molecular epidemiology
  • RhoC
  • Tumor emboli

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Molecular epidemiologic features of inflammatory breast cancer : A comparison between Egyptian and US patients. / Lo, An Chi; Kleer, Celina G.; Banerjee, Mousumi; Omar, Sherif; Khaled, Hussein; Eissa, Saad; Hablas, Ahmed; Douglas, Julie A.; Alford, Sharon H.; Merajver, Sofia D.; Soliman, Amr S.

In: Breast Cancer Research and Treatment, Vol. 112, No. 1, 01.11.2008, p. 141-147.

Research output: Contribution to journalArticle

Lo, AC, Kleer, CG, Banerjee, M, Omar, S, Khaled, H, Eissa, S, Hablas, A, Douglas, JA, Alford, SH, Merajver, SD & Soliman, AS 2008, 'Molecular epidemiologic features of inflammatory breast cancer: A comparison between Egyptian and US patients', Breast Cancer Research and Treatment, vol. 112, no. 1, pp. 141-147. https://doi.org/10.1007/s10549-007-9833-z
Lo, An Chi ; Kleer, Celina G. ; Banerjee, Mousumi ; Omar, Sherif ; Khaled, Hussein ; Eissa, Saad ; Hablas, Ahmed ; Douglas, Julie A. ; Alford, Sharon H. ; Merajver, Sofia D. ; Soliman, Amr S. / Molecular epidemiologic features of inflammatory breast cancer : A comparison between Egyptian and US patients. In: Breast Cancer Research and Treatment. 2008 ; Vol. 112, No. 1. pp. 141-147.
@article{89b9cb0bb872428a943a93874d2ae4ea,
title = "Molecular epidemiologic features of inflammatory breast cancer: A comparison between Egyptian and US patients",
abstract = "Background: Inflammatory breast cancer (IBC) is a lethal form of breast cancer with unknown etiology. A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors. Methods: We used tumor blocks and demographic, epidemiologic, and clinical data of 48 IBC patients from Egypt and 12 patients from the United States. We counted tumor emboli in tumors before and after immunohistochemical staining with lymphatic vessel endothelial receptor-1 (LYVE-1), and measured the expression of RhoC GTPase protein in the two groups. Results: Erythema, edema, and peau d'orange were found in 77{\%} of the Egyptian patients as compared with 29{\%} found in the US patients (P = 0.02). The number of tumor emboli was significantly higher in tumors from Egypt (mean ± SD, 14.1 ± 14.0) than in the tumors from the United States (5.0 ± 4.0, P = 0.01). The number of tumor emboli in LYVE-1 positive vessels was higher in tumors from Egypt (3.5 ± 2.8) than tumors from the United States (1.6 ± 0.5, P = 0.15). We detected a high level of RhoC in 87{\%} of the tumors from Egypt and 14{\%} of the tumors from the United States (P = 0.0003). Conclusion: Patients from Egypt have a more aggressive form of IBC than those in the United States. Our analysis of IBC patients shows that distinct molecular phenotypes can be found when these two study populations are compared. Future studies should explore the epidemiologic and environmental exposures and the genetic factors that might lead to the different clinical and molecular features of IBC in patients from these two countries.",
keywords = "Inflammatory breast cancer, International, LYVE-1, Molecular epidemiology, RhoC, Tumor emboli",
author = "Lo, {An Chi} and Kleer, {Celina G.} and Mousumi Banerjee and Sherif Omar and Hussein Khaled and Saad Eissa and Ahmed Hablas and Douglas, {Julie A.} and Alford, {Sharon H.} and Merajver, {Sofia D.} and Soliman, {Amr S.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1007/s10549-007-9833-z",
language = "English (US)",
volume = "112",
pages = "141--147",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Molecular epidemiologic features of inflammatory breast cancer

T2 - A comparison between Egyptian and US patients

AU - Lo, An Chi

AU - Kleer, Celina G.

AU - Banerjee, Mousumi

AU - Omar, Sherif

AU - Khaled, Hussein

AU - Eissa, Saad

AU - Hablas, Ahmed

AU - Douglas, Julie A.

AU - Alford, Sharon H.

AU - Merajver, Sofia D.

AU - Soliman, Amr S.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: Inflammatory breast cancer (IBC) is a lethal form of breast cancer with unknown etiology. A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors. Methods: We used tumor blocks and demographic, epidemiologic, and clinical data of 48 IBC patients from Egypt and 12 patients from the United States. We counted tumor emboli in tumors before and after immunohistochemical staining with lymphatic vessel endothelial receptor-1 (LYVE-1), and measured the expression of RhoC GTPase protein in the two groups. Results: Erythema, edema, and peau d'orange were found in 77% of the Egyptian patients as compared with 29% found in the US patients (P = 0.02). The number of tumor emboli was significantly higher in tumors from Egypt (mean ± SD, 14.1 ± 14.0) than in the tumors from the United States (5.0 ± 4.0, P = 0.01). The number of tumor emboli in LYVE-1 positive vessels was higher in tumors from Egypt (3.5 ± 2.8) than tumors from the United States (1.6 ± 0.5, P = 0.15). We detected a high level of RhoC in 87% of the tumors from Egypt and 14% of the tumors from the United States (P = 0.0003). Conclusion: Patients from Egypt have a more aggressive form of IBC than those in the United States. Our analysis of IBC patients shows that distinct molecular phenotypes can be found when these two study populations are compared. Future studies should explore the epidemiologic and environmental exposures and the genetic factors that might lead to the different clinical and molecular features of IBC in patients from these two countries.

AB - Background: Inflammatory breast cancer (IBC) is a lethal form of breast cancer with unknown etiology. A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors. Methods: We used tumor blocks and demographic, epidemiologic, and clinical data of 48 IBC patients from Egypt and 12 patients from the United States. We counted tumor emboli in tumors before and after immunohistochemical staining with lymphatic vessel endothelial receptor-1 (LYVE-1), and measured the expression of RhoC GTPase protein in the two groups. Results: Erythema, edema, and peau d'orange were found in 77% of the Egyptian patients as compared with 29% found in the US patients (P = 0.02). The number of tumor emboli was significantly higher in tumors from Egypt (mean ± SD, 14.1 ± 14.0) than in the tumors from the United States (5.0 ± 4.0, P = 0.01). The number of tumor emboli in LYVE-1 positive vessels was higher in tumors from Egypt (3.5 ± 2.8) than tumors from the United States (1.6 ± 0.5, P = 0.15). We detected a high level of RhoC in 87% of the tumors from Egypt and 14% of the tumors from the United States (P = 0.0003). Conclusion: Patients from Egypt have a more aggressive form of IBC than those in the United States. Our analysis of IBC patients shows that distinct molecular phenotypes can be found when these two study populations are compared. Future studies should explore the epidemiologic and environmental exposures and the genetic factors that might lead to the different clinical and molecular features of IBC in patients from these two countries.

KW - Inflammatory breast cancer

KW - International

KW - LYVE-1

KW - Molecular epidemiology

KW - RhoC

KW - Tumor emboli

UR - http://www.scopus.com/inward/record.url?scp=52949143119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949143119&partnerID=8YFLogxK

U2 - 10.1007/s10549-007-9833-z

DO - 10.1007/s10549-007-9833-z

M3 - Article

C2 - 18058225

AN - SCOPUS:52949143119

VL - 112

SP - 141

EP - 147

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -